Abstract

Confirmation and prevention of targeted toxicity by a recombinant fusion toxin

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Modulation of the Apoptotic Response of Human Myeloid Leukemia Cells to a Diphtheria Toxin Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein
Joseph Vesely ... Arthur E Frankel
Blood | VOL. 90
Joseph Vesely, et. al.Joseph Vesely ... Arthur E Frankel
01 Nov 1997
A Recombinant fusion toxin targeted to the granulocyte-Macrophage colony-Stimulating factor receptor
Yu Shao ... Stella M Davies
Leukemia & Lymphoma | VOL. 25
Yu Shao, et. al.Yu Shao ... Stella M Davies
01 Jan 1997
Up-regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in murine peritoneal exudate macrophages by both GM-CSF and IL-3.
L Sensenbrenner ... K Fan
The Journal of Immunology | VOL. 149
L Sensenbrenner, et. al.L Sensenbrenner ... K Fan
01 Jul 1992
The Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF ) Receptor Exists as a Preformed Receptor Complex That Can Be Activated by GM-CSF, Interleukin-3, or Interleukin-5
Joanna M Woodcock ... Christopher J Bagley
Blood | VOL. 90
Joanna M Woodcock, et. al.Joanna M Woodcock ... Christopher J Bagley
15 Oct 1997
View more papers

More From: Molecular Cancer Therapeutics

Paper Title
Journal
Date
Author
Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors.
Amy E Anderson ... Christine E Bowman
Molecular cancer therapeutics | VOL. -
Amy E Anderson, et. al.Amy E Anderson ... Christine E Bowman
27 May 2024
Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues.
Jennifer H E Baker ... Andrew I Minchinton
Molecular cancer therapeutics | VOL. -
Jennifer H E Baker, et. al.Jennifer H E Baker ... Andrew I Minchinton
23 May 2024
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Anran Chen ... Matthew J Ellis
Molecular cancer therapeutics | VOL. -
Anran Chen, et. al.Anran Chen ... Matthew J Ellis
23 May 2024
IL-15/IL-15Rα-Fc fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T cell expansion.
Ji Li ... Teemu T Junttila
Molecular cancer therapeutics | VOL. -
Ji Li, et. al.Ji Li ... Teemu T Junttila
13 May 2024
View more papers